The first MEK1/2 inhibitor PD098059 was followed by trametinib (MEKinistTM), as the first clinically useful MEK inhibitor applied as agent to treat BRAF-mutated melanomas [69–71]. This evidence concerns the gene MAP2K7 and melanoma.